Revolutionize Your Medical Affairs Focus with Glean Insights
How Can We Help?
At Glean Insights, we are your trusted partner throughout the entire product lifecycle, catering to the unique needs of both early-stage organizations and fully commercialized teams. Our expertise spans a wide range of essential services, including external KOL engagement, scientific platform and lexicon refinement, publication planning and review processes, biomarker strategy development, early access planning and timing, congress strategy, HEOR planning, medical affairs team deployment timelines, creation of essential SOPs and compliance policies, and comprehensive medical affairs strategy development. We also provide guidance on how and when to deploy grant programs, medical education initiatives, and Investigator-Initiated Trials (IITs), and we can assist in the recruitment of top-notch medical team members. Whatever stage your product is in, we're here to empower your success.
Early/ Pre-Clinical Stage
We offer more directional and higher level guidance in this early stage of your company. We understand cost limitations but also the need to ensure that you and your team are set up for success as your programs evolve. To this end, we can provide directional feedback on your current systems and processes and highlight what to watch out for and when to start thinking about specific medical capabilities
Clinical/ Pre-commercial Stage
We are here to provide specific guidance on medical team timing and deployment, basic medical affairs strategies and external engagement planning. Additionally, we can start getting more tactical with ad hoc project support and even assist to hire first your medical employees to ensure proper match of needs and skills
Commercial Stage
We can support you and your company through process refinement and fine tuning of team structures, efficiencies, communication, and medical affairs strategies. We are also able to help bridge regional focus to global focus (ie companies expressly focused on US now looking to bridge to EU, AP, etc) and help develop more comprehensive and tailored medical strategies